NCT07552324Not yet recruitingPhase 2
Study on the Treatment of Double/Triple-hit Diffuse Large B-cell Lymphoma With Chidamide and Lisaftoclax in Combination With Vepesidil, Rituximab, Cyclophosphamide, Adriamycin, and Prednisone (CL-Pola-R-CHP)
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Not yet recruiting
- Sponsor
- Ruijin Hospital
- Enrollment
- 28
- Primary Endpoint
- Complete remission (CR) rate
Study Overview
Brief Summary
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation. The study employs a 6-cycle CL-Pola-R-CHP regimen, with cycles repeated every 21 days.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 65 Years to — (Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Histopathological diagnosis confirmed as diffuse large B-cell lymphoma, with CD20 positivity;
- •Double or triple hit confirmed by pathology;
- •Age ≥ 65 years old;
- •ECOG performance status score of 0, 1, or 2;
- •No history of malignant tumor; no concurrent occurrence of other tumors;
- •Patients whose life expectancy is at least 6 months, as determined by the researcher;
- •The patient or their legal guardian must provide written informed consent before undergoing any special examinations or procedures in the study.
- •International Prognostic Index (IPI) > 1 point.
Exclusion Criteria
- •There is a history of other malignant tumors, excluding basal cell carcinoma and cervical carcinoma in situ;
- •Accompanied by uncontrolled cardiovascular and cerebrovascular diseases, coagulation disorders, connective tissue diseases, severe infectious diseases, etc;
- •Primary central nervous system lymphoma;
- •Left ventricular ejection fraction (LVEF) is less than or equal to 50%;
- •Laboratory test values during screening: (unless caused by lymphoma); A. Neutrophil count <1.5*10^9/L; B. Platelet count <75*10^9/L; C. ALT or AST is more than twice the upper limit of normal, and AKP and bilirubin are more than 1.5 times the upper limit of normal; D. Creatinine level is higher than 1.5 times the upper limit of normal;
- •Other concurrent and uncontrolled medical conditions that the researcher believes will affect the patient's participation in the study.
- •Patients with mental illness or other patients known or suspected to be unable to fully comply with the study protocol;
- •Pregnant or lactating women;
- •HIV-infected individuals.
- •Patients with positive HBsAg test results must undergo HBV DNA testing and can only be enrolled after becoming negative. Additionally, if the HBsAg test result is negative but the HBcAb test result is positive (regardless of the HBsAb status), HBV DNA testing is also required. If the result is positive, treatment must be administered until becoming negative before enrollment;
Arms & Interventions
Treatment Group
Experimental
CL-Pola-R-CHP
Intervention: CL-Pola-R-CHP (Drug)
Outcomes
Primary Outcomes
Complete remission (CR) rate
Time Frame: End of treatment visit (6-8 weeks after last dose on Day 1 of Cycle 6 [Cycle length=21 days]
Secondary Outcomes
- 1-year progression-free survival (PFS) rate(1 years after enrollment)
- 2-year overall survival (OS) rate(2 years after enrollment)
Investigators
Similar Trials
Not yet recruiting
Phase 4
A clinical trial to study and compare the effect of two different antibiotic regimen in treating Helicobacter pylori infection.CTRI/2024/09/073256Intramural Research Fund Committee168
Recruiting
Not Applicable
Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudyNCT07398599Second Affiliated Hospital of Nanchang University30
Recruiting
Phase 4
Efficacy of Triple versus Dual Therapy in COPD Using Surfactant Protein-D as a BiomarkerCTRI/2025/02/080369SRMIST224
Recruiting
Phase 1
Treatment of Participants With Primary or Secondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisMultiple SclerosisNCT07477639Tr1X, Inc.39
Not yet recruiting
Not Applicable
A Clinical Study to Test the Safety and efficacy of test treatment for improving visible signs of facial aging such as wrinkles, fine lines, and dark spots.CTRI/2025/07/091149Ambe Phytoextracts Pvt. Ltd81
